drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
CAR T cells engineered via lentiviral vector to target CD5; IV administration with dose escalation; intended to eliminate CD5+ T-cell malignancies through CAR signaling and effector functions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous or allogeneic T cells are lentivirally engineered to express a CD5-specific chimeric antigen receptor. Upon binding CD5 on malignant T cells, the CAR provides MHC-independent activation, leading to T-cell expansion and perforin/granzyme-mediated cytotoxicity with cytokine release, eliminating CD5-positive tumor cells.
drug_name
CD5-directed CAR T cells
nct_id_drug_ref
NCT06849921